Ex vivo modeling of the effects of mycophenolic acid on HIV infection: Considerations for antiviral therapy

AIDS Research and Human Retroviruses

Volumn 21, Issue 2, 2005, Pages 116-124

  Kaur, Rupinderjeet ^a   Klichko, Vladimir ^a,b   Margolis, David ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b N Texas Vet Health Care Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYTOCHROME C OXIDASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; LYMPHOCYTE ACTIVATION; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS REPLICATION;

APOPTOSIS; CELLS, CULTURED; ELECTRON TRANSPORT COMPLEX IV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MYCOPHENOLIC ACID; RANTES; RECEPTORS, CCR5; RNA, MESSENGER;

EID: 14844364375     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.116     Document Type: Article

References (40)

1. Pierson T, McArthur J, and Siliciano RF: Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000;18:665-708.
2. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, and Margolis DM: A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001;26:423-434.
3. Press N, Kimel G, Harris M, Yip B, Craib KJ, and Montaner JS: Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens. HIV Clin Trials 2002;3:17-20.
4. Margolis DM, Kewn S, Coull JJ, et al.: The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002;31:45-49.
5. Heredia A, Margolis D, Oldach D, Hazen R, Le N, and Redfield R: Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999;22:406-407.
6. Allison AC and Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
7. Ichimura H and Levy JA: Polymerase substrate depletion: A novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-560.
8. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, and Redfield R: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21:362-370.
9. Hossain MM, Coull JJ, Drusano GL, and Margolis DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002;55:41-52.
10. Borroto-Esoda K, Wakefield DJ, Myrick F, Painter G, and Furman P: The effect of mycophenolic acid and ribavirin on the antiviral activity of amdoxivir. Antiviral Ther 2001;6(S1):9.
11. Chapuis AG, Paolo Rizzardi G, D'Agostino C, et al.: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6:762-768.
12. Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, and Jay CA: Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994;35:482-487.
13. Lai KK, Gang DL, Zawacki JK, and Cooley TP: Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 1991;115:283-284.
14. Sundar K, Suarez M, Banogon PE, and Shapiro JM: Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature. Crit Care Med 1997;25:1425-1430.
15. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
16. Lin YL, Mettling C, Portales P, Reynes J, Clot J, and Corbeau P: Cell surface CCR5 density determines the post-entry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 2002;99: 15590-15595.
17. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
18. Paxton WA, Dragic T, Koup RA, and Moore JP: The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. AIDS Res Hum Retroviruses 1996;12:1203-1207.
19. Zagury D, Lachgar A, Chams V, et al.: C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998;95:3857-3861.
20. Ferbas J, Giorgi JV, Amini S, et al.: Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000;182:1247-1250.
21. Cocchi F, DeVico AL, Yarchoan R, et al.: Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000;97:138I2-13817.
22. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
23. Jamieson BD and Zack JA: In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998;72: 6520-6526.
24. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, et al.: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-1943.
25. Birkus G, Hitchcock MJ, and Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.
26. Muthumani K, Choo AY, Hwang DS, et al.: Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun 2003;304:583-592.
27. Re F, Braaten D, Franke EK, and Luban J: Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995;69:6859-6864.
28. He J, Choe S, Walker R, Di Marzio P, Morgan DO, and Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995;69:6705-6711.
29. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, and Chen IS: The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995;69:6304-6313.
30. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, and Chen IS: Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol 1996;70:2516-2524.
31. Goh WC, Rogel ME, Kinsey CM, et al.: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo. Nat Med 1998;4:65-71.
32. Quemeneur L, Flacher M, Gerland LM, Ffrench M, Revillard JP, and Bonnefoy-Berard N: Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002;169:2747-2755.
33. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, and Brayman KL: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3:534-542.
34. Cooper CE, Nicholls P, and Freedman JA: Cytochrome c oxidase: Structure, function, and membrane topology of the polypeptide sub-units. Biochem Cell Biol 1991;69:586-607.
35. Garcia-Benayas T, Blanco F, de la Cruz JJ, Soriano V, and Gonzalez-Lahoz J: Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003;17:921-924.
36. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, and Mallal SA: Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003;8:323-331.
37. Gougeon ML: Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003;3:392-404.
38. Silvestri G and Feinberg MB: Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 2003;112: 821-824.
39. Kinter A, Moorthy A, Jackson R, and Fauci AS: Productive HIV infection of resting CD4+ T cells: Role of lymphoid tissue microenvironment and effect of immunomodulating agents. AIDS Res Hum Retroviruses 2003;19:847-856.
40. Hutchinson P, Jose M, Atkins RC, and Holdsworth SR: Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment. Transpl Immunol 2004;13:55-61.